There is growing recognition that cognitive impairment is a prevalent comorbidity and consequence of both type 1 and type 2 diabetes.^1,2 Diabetes has been linked to subtle cognitive changes in people of all ages, but those 60 and older are more at risk for overt dementia and cognitive impairment.³ The effects of cognitive decline are widespread. A higher risk of cardiovascular events and mortality, as well as a higher frequency of severe hypoglycemic episodes, are linked to worse diabetes control.^4,5 In order to prevent hypoglycemia and increase compliance, diabetes guidelines advise screening for cognitive impairment in those over 65 with diabetes and recommend that therapy for those with cognitive impairment be customized.^4–6

Therefore, the focus of diabetes-related cognitive impairment has shifted from research to therapeutic treatment. But there are still significant issues. The causal relationship between diabetes and certain alterations in the brain is unclear. Furthermore, nothing is known about the underlying processes. For instance, the burden of Alzheimer’s disease (AD) neuropathology does not seem to be higher in people with diabetes, despite strong epidemiological evidence that diabetes increases the incidence of dementia, including AD.^7,8 Furthermore, diabetes does not seem to be the main cause of the elevated risk for dementia,⁹ despite the fact that it is linked to cerebrovascular illness and an increased risk of stroke.¹⁰ Other pathways, some of which may be directly related to the diabetic condition, are being discovered.

Additional mechanisms are being identified, including some that might be directly linked to the diabetic state, such as brain amylin buildup and insulin resistance.¹⁰ Because of this, cognitive impairment in diabetes is probably caused by a variety of etiologies, some of which are unique to diabetes and many of which are not, resulting in mixed pathologies that vary significantly between individuals.¹⁰ The diagnosis, prevention, and treatment of cognitive impairment linked to diabetes are complicated by this finding. With an emphasis on type 2 diabetes, this review demonstrates how biomarker techniques might help clarify the intricate etiology of diabetes-associated cognitive impairment.

Cognitive dysfunction or AD stands a neurological condition that is prevalent in the elderly. Various degrees of memory, behavioral, and cognitive impairment exist in people. The majority of those who have the condition gradually lose their capacity to remember things, think clearly, and even complete simple tasks. In those who have the late-onset type of the disease, symptoms start to show in their mid-sixties. Approximately 18% of the world’s population is affected by neuropsychiatric disorders. Their cognitive, memory, emotional, and social functioning decline. AD is to blame for 70% of dementia cases worldwide.^11–13 AD has a variety of causes, including deficits in vitamins, diabetes, persistent alcohol misuse, psychiatric illnesses, subdural hematomas, neurological disorders, sadness, infections (HIV), and mental dysfunction brought on by chemotherapy.¹⁴ Early-stage AD progressively becomes worse and is ignored. The patient frequently loses track of time and is disoriented. The symptoms are clearer and more visible to the caregivers on the middle face. They describe symptoms such as difficulty swallowing and ingestion, stability issues, verbal and dialogue problems, memory loss that causes them to forget names of people or things, adjustments in conduct, uneasiness, wandering, and persistent questioning, and amnesia of recent events and names. They frequently needed extra assistance with concentration, communication, and problem-solving. The penultimate phase is characterized by memory disturbance. People are unable to recognize local relatives, locations, or activities. There is hostility, sobbing, or fury.^15–17 Hallucinations, nervousness, despair, anxiety, impulsive behavior, elation, laziness, irritability, delusions, abnormal motor activity, and changes in food or sleep are a few of the behavioral and psychological signs of AD. Due to the disease’s protracted effects, which include hospital stays and medical costs, AD patients typically have poor outcomes. It involves drug abuse as well as the agitation or discomfort of the patients and the caregivers. Patients might experience multiple symptoms at once or just one.¹⁸

Diabetes mellitus (DM) is categorized by chronic hyperglycemia and abnormalities in the uptake of celluloses, fats, and proteins. It is raised by an inadequacy in insulin secretion and/or action, either completely or in part. The two principal types of diabetes are type 1 diabetes mellitus (T1DM), an insulin-dependent type of diabetes, and non-insulin-dependent diabetes mellitus type 2 diabetes mellitus (T2DM). The most typical kind of diabetes, T2DM, affects 90–95% of all diabetic patients.¹⁹ Type 1 diabetes is mostly a hereditary problem that manifests in adolescence, whereas type 2 diabetes is primarily a diet-related condition that appears over time. In persons with type 1 diabetes, their immune structure is violent and ends the insulin-producing cells inside the human pancreas.²⁰ T2DM symptoms include hyperglycemia, glucose intolerance, and a comparative lack of insulin. These results from decreased insulin susceptibility of muscle, hepatic, and adipocytes (also called insulin resistance). In general, the pancreas increases its synthesis of insulin right after eating. Insulin targets the muscle strength, adipose, hepatic, and acellular. Insulin boosts sugar from the blood and helps glycol genesis by restricting glycogen synthesis. Islet amyloid polypeptide in humans (hIAPP, amylin), which causes pancreatic β cell malfunction, is another characteristic of diabetes. Chronic hyperglycemia is the direct source of numerous diabetic indications, including retinopathy, peripheral neuropathy, and nephropathy, as a result of the ensuing metabolic disruption.^21–23 The interplay of genetic, environmental, and other risk factors primarily causes T2DM. Additionally, diminished first-phase insulin release, aberrant baseline pulsatile insulin excretion, and elevated glucagon production all hasten the onset of Form II DM.²⁴

Type 2 diabetes is linked to AD virus, the most frequent condition of dementia. Various researchers who have studied massive populations for so many decades suggest that those with type 2 diabetes may be further prone to grow AD. Some individuals refer to AD as “type 3 diabetes.” Along with malfunction, the action of glucose engagement in the neurons for liveliness manufacture in T2DM is highly associated with cognitive impairment, according to substantial epidemiological evidence. The complicated connection between T2DM and AD is influenced by oxidative stress, inflammation, glycogen synthase kinase 3β (GSK3β) signaling, amyloid beta (Aβ) production from amyloid precursor protein (APP), the development of neurofibrillary tangles, and modulation of acetylcholine esterase activity. Due to common devices of T1DM, T2DM, and AD, scholars established the term “type 3 diabetes.” The goal of the review article is to talk about cellular and molecular associations between diabetes and AD, which are destined for type 3 diabetes.^25–27 The terminology was proposed by some scientists because they think dementia is brought on by insulin imbalance in the brain. The supposed AD gene mutation APOE4 appears to get in the way of the use of insulin by brain cells, potentially leading to starvation and death. It is mentioned as type 3 diabetes informally.²⁸ AD rates may have increased because of the epidemic of insulin resistance, pre-diabetes, and type 2 diabetes. According to recent studies, there is a clear association between AD and sugar imbalance.²⁹ APP, amyloid-β (APP-Aβ) deposit, cell loss, a lot of neurofibrillary tangles, dystrophic neuritis, amplified beginning of pre-death genetic factor and signing pathway, impaired energy metabolism, mitochondrial flawed, long-term oxidative trauma, also DNA injury are all hallmarks of AD. A framework that mechanistically connects all these occurrences is necessary to better understand AD pathogenesis. There is currently a rapid expansion of research pointing to insulin conflict and deficit as mediating factors in AD-type neurodegeneration, but there are many unclear as well as conflicting theories about potential functions of T2DM, the metabolic disorders, and other conditions in this deluge of updated information and obesity in AD pathogenesis. In this article, we analyze the data showing that:

We come to the conclusion that AD is described as a category of diabetes. It possesses molecular and biological features and is uniquely associated with the brain with both type 1 diabetes mellitus and T2DM. The term “type 3 diabetes” correctly captures this.^30–33 We have elaborated on the possible biological pathways linking T2DM and AD. Specifically, we discussed the roles of insulin resistance, chronic hyperglycemia-induced oxidative stress, and inflammation in neuronal damage and impaired glucose metabolism in the brain. In clinical practice, it is preferable to categorize these patients’ symptoms in order to estimate prognosis, treatment response, and illness natural cores. Some of these elements apply to them. The greatest risk factor is age. As people age, their symptoms get worse. A larger risk exists for first-degree relatives of AD patients. Other risk factors include dietary habits, diabetes, and hypertension, as well as the level of mental activity over the course of a lifetime.³³ Reduced glucose utilization is a common aspect of AD, and insulin therapy has been revealed to improve memory. According to reports, IRs and insulin levels in AD patients are lower than in normal persons; hence, raising insulin levels can enhance cognition. Clinical studies have shown that administering insulin along with other anti-diabetic drugs will lessen plaque buildup and enhance reasoning piece in AD patients with DM. The current investigation will highlight a strong relationship between insulin dysregulation in the mind and AD.³⁴ Low stages of B12 might create high homocysteine levels, which can affect some brain cells. Your brain messages become distorted as a result, resulting in mood changes and even anxiety. Potential AD treatments that stop the fundamental disease processes have been made possible by our increased understanding of how the illness affects the brain. Future AD treatments might involve a combination of drugs, much like how HIV/AIDS or cancer treatments might involve more than one therapy.

A total number of 300 persons were included in this study. That shows the socio-demographic characteristics of the patients. The average oldness of the patients is 58 years, ranging from 25 to 94. Graph 1 shows the mean time of life of the AD patients is 58 years, in which the minimum age of patients is 42 and the maximum age is 88. The study reveals the demographic status of gender distribution among males and females. There are more female patients (68.85%) in comparison to male patients (31%). Graph 2 shows the relative ratio of AD among genders. The ratio of female patients (68.85%) is higher compared to male patients (31%).

This study reveals the mean values, standard deviation, and significant difference of AD patients in comparison with control group. The mean ± SD (10.8 ± 2.51234) of the hemoglobin parameters of AD patients is lower than the normal range. On the basis of the t-test, noteworthy changes (p-value < 0.0001) exist in hemoglobin levels in the control group vs. AD patients. The mean ± SD (4.2 ± 0.29) of the RBC parameter of AD patients is lower than the normal range. On the basis of the t-test, important modifications (p-value < 0.0001) exist at the RBC levels in the control group vs. AD patients. The mean ± SD (7.5 ± 1.6) of the WBC parameter of AD patients is lower than the normal range. On the basis of the t-test, weighty alterations (p-value < 0.0413) exist at WBC levels in the control group vs. AD patients. The mean ± SD (208.25 ± 83.24) of the platelet parameter of AD patients is lower than the normal range. On the basis of t-test, noteworthy modifications (p-value < 0.0001) exist in platelets levels in the control group vs. AD patients. The mean ± SD (54.25 ± 10.156) of the neutrophil parameter of AD patients is lower than the normal range. According to the t-test, significant differences (p-value < 0.0001) exist in neutrophil levels in the control group vs. AD patients. The mean ± SD (31.6067 ± 9.0767) of the lymphocyte parameter of AD patients is lower than the normal range. From the t-test, noteworthy transformations (p-value < 0.0060) exist in lymphocyte levels in the control group vs. AD patients. The mean ± SD (80.92 ± 8.0377) of the MCV parameter of AD patients is lower than the normal range. From the t-test, noteworthy differences (p-value < 0.0042) exist in MCV levels in the control group vs. AD patients. The mean ± SD (25.98 ± 3.77) of MCH parameter of AD patients is lower than the normal range. According to the t-test, significant differences (p-value < 0.0001) exist in MCH levels in the control group vs. AD patients. The mean ± SD (31.31 ± 2.035) of the MCHC parameter of AD patients is lower than the normal range. On the basis of t-test, significant changes (p-value < 0.0001) exist in MCHC levels in the control group vs. AD patients. The mean ± SD (39.87 ± 4.84) of the PVC (HCT) parameter of AD patients is lower than the normal range. From the t-test, important differences (p-value < 0.0001) exist in PVC (HCT) levels in the control group vs. AD patients. Table 2 shows the significant association of levels of hematological indices in AD patients in comparison with control group. The control group takes the usual values of almost all limits; however, in the patients’ group (AD), the average value of each parameter is less than the normal range. Low levels were analyzed in hematological indices in all AD patients. Graphs shows the levels of relationships between AD patients and controls that are independent of each other. The table shows a significant association of p < 0.050.

The study reveals the mean value, standard deviation, and significant difference of AD patients in comparison with control group. The mean ± SD (8.99 ± 3.1) of the HbA1c parameter of AD patients is higher than the normal range. On the basis of the t-test, significant alterations (p-value < 0.0001) exist in HbA1c levels in the control group vs. AD patients. Table 3 shows the level of HbA1c among AD patients and control group. This shows a significant association between insulin levels among AD patients. The graph shows the relationships between AD patients and controls that are self-regulating of each other. The tallness or distance of the bar designates the measured value of incidence.

This study reveals the mean value, standard deviation, and significant difference of AD patients in comparison with control group. The mean ± SD (8.99 ± 3.1) of the vitamin B12 parameter of AD patients is less than the normal range. From the t-test, significant changes (p-value < 0.0001) exist in vitamin B12 levels in the control group vs. AD patients. Table 4 shows the level of HbA1c among AD patients and control group. This shows a significant association between insulin levels among AD patients. The graph shows the relationships between AD patients and controls that are self-determining of each other. The altitude or dimension of the bar shows the controlled price of consistency. Further analysis of gender differences observed in hematological and biochemical parameters among AD and T2DM patients through hormonal differences, lifestyle factors, and differential disease progression between males and females could contribute to the disparities in our data. The limitation of not employing standardized cognitive scales like the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) in our current study is acknowledged, and its inclusion in future research to validate clinical dementia diagnoses and better correlate hematological/metabolic changes with cognitive decline is suggested.

This study highlights a significant association between AD and diabetes mellitus, emphasizing the role of metabolic and hematological alterations in cognitive decline. The marked differences observed in CBC parameters, HbA1c, and vitamin B12 levels between AD patients and healthy individuals (p < 0.0001) suggest that disrupted blood profiles, particularly poor glycemic control, may contribute to the pathophysiological mechanisms underlying AD. The higher prevalence of AD among females and the abnormal hematological indices further reinforce the need for routine metabolic and blood parameter monitoring, especially in elderly diabetic populations. Early detection through such screenings could play a crucial role in preventing or delaying cognitive dysfunction. Future research should explore the gender disparities and complex biological pathways linking diabetes and AD for more targeted intervention strategies.